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Following estrogenic activation, the estrogen receptor- (ER) di-
rectly regulates the transcription of target genes via DNA binding.
MicroRNAs (miRNAs) modulated by ER have the potential to fine
tune these regulatory systems and also provide an alternate mech-
anism that could impact on estrogen-dependent developmental and
pathological systems. Through a microarray approach, we identify
the subset of microRNAs (miRNAs) modulated by ER, which include
upregulation of miRNAs derived from the processing of the paralo-
gous primary transcripts (pri-) mir-17–92 and mir-106a-363. Charac-
terization of themir-17–92 locus confirms that the ER target protein
c-MYC binds its promoter in an estrogen-dependent manner. We
observe that levels of pri-mir-17–92 increase earlier than the mature
miRNAs derived from it, implicating precursor cleavage modulation
after transcription. Pri-mir-17–92 is immediately cleaved by DROSHA
to pre-miR-18a, indicating that its regulation occurs during the for-
mation of the mature molecule from the precursor. The clinical
implications of this novel regulatory system were confirmed by
demonstrating that pre-miR-18a was significantly upregulated in
ER-positive compared to ER-negative breast cancers. Mechanisti-
cally, miRNAs derived from these paralogous pri-miRNAs (miR-18a,
miR-19b, and miR-20b) target and downregulate ER, while a subset
of pri-miRNA-derived miRNAs inhibit protein translation of the ER
transcriptional p160 coactivator, AIB1. Therefore, different subsets of
miRNAs identified act as part of a negative autoregulatory feedback
loop. We propose that ER, c-MYC, and miRNA transcriptional pro-
grams invoke a sophisticated network of interactions able to provide
the wide range of coordinated cellular responses to estrogen.
AIB1  autoregulatory feedback loop  primary transcript  processing
Upon 17--estradiol (E2) binding, estrogen receptors (ERs)mediate transcription by interacting directly to specific
estrogen response elements (EREs) located in the promoter/
enhancer region of its target genes or indirectly by tethering to
nuclear proteins, such as AP1 and SP1 transcription factors
(2–4). The cellular response to estrogen is highly regulated at
multiple levels including transcription, RNA stability, and post-
translational modifications (5–8). Following treatment with E2,
ER transcription and mRNA stability is substantially reduced
within 1 h of stimulation (7). Furthermore, E2–ER interactions
accelerate receptor degradation through the ubiquitin–
proteasome pathway, an effect associated with its major coac-
tivator AIB1 (8).
MicroRNAs (miRNAs) are a class of noncoding short RNAs,
21–24 nucleotides (nt) in length, that play a role in gene regulation.
They downregulate expression of their target genes by base pairing
to the 3-UTR of target messenger RNAs (mRNAs) (9). During
their biogenesis most miRNAs are transcribed as part of a longer
transcript named pri-miRNA (10). These molecules are processed
inside the nucleus by DROSHA, producing a pre-miRNA that is a
70-nt ‘‘imperfect’’ stem loop RNA actively transported into the
cytoplasm. In the cytoplasm the pre-miRNA is cleaved by DICER,
a dual processing event that releases a small double stranded RNA,
about 22 nt in length. Here, nuclear processing activity is thought
to be regulated at early stages of development and in a variety of
tumor cells (11–13). There is also evidence of regulation at the next
step, pre-miRNA precursor processing (14, 15). After formation of
the small duplex RNA, only 1 strand is loaded onto a miRNA
induced silencing complex (RISC). These RISCs, guided by their
miRNA, interact with the 3-UTR or sometimes with the coding
region of targetmRNAs, inhibiting protein translation or degrading
the mRNA target (10).
Substantial data associate changes in miRNA activity with car-
cinogenesis and progression (16–19). The humanmir-17–92 cluster
is a polycistronic gene with a chromosomal location 13q31-q32 that
encodes 6 miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-
19b-1, and miR-92–1). Ancient duplications have given rise to 2
mir-17–92 paralogues in mammals: mir-106b-25 and mir-106a-363.
Mir-17–92 is thought to be oncogenic in lung cancer and lympho-
mas (17, 20) or function as a tumor suppressor in breast cancer by
downregulating AIB1 and/or cyclin D1 (21, 22). Furthermore, the
genomic 13q31 area including mir-17–92 is correlated with loss of
heterozygosity in breast cancer (23).
By a genome wide approach, we have elucidated the miRNAs
regulated by ER in breast cancer. Here, we show that among the
few miRNAs upregulated by ER, miR-18a encoded by the pri-
mir-17–92, miR-19b encoded by both this primary transcript and its
evolutionary paralogue pri-mir-106a-363, and miR-20b encoded by
pri-mir-106a-363, downregulate ER expression at the protein
translational level, correlating the induction of these 2 genes during
cell proliferation with a negative feedback loop. Remarkably,
miR-20b also downregulates and targets theER coactivatorAIB1.
Since ER can act as a ligand-activated oncogene, we suggest that
the pri-mir-17–92 acts as a tumor suppressor in breast cancer, not
only by downregulating cyclin D1 and AIB1 via the miR-17/20/106
family, but also by downregulation of ER by miR-18, miR-19, and
miR-17/20/106 members. For the first time we correlate ER
translational control by miRNAs as a further regulatory process
involved in ER transcriptional activity after ligand stimulation.
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Results
ER Induction Reveals pri-mir-17–92 Upregulation. To determine
whether ER regulates the expression of miRNAs, E2 was added
to MCF-7 cells and miRNA chip hybridization was performed to
elucidate early (0–3 h) and delayed (6 h) regulation of miRNAs
by ER. As a control we used an MCF-7-TO (MCF-7-Tet-Off)-
derived cell line, JP13, that conditionally overexpresses a protein
composed of the zinc finger transcriptional repressor PLZF fused
to ER (PLZF-ER), acting as a dominant-negative that inhibits
expression of estrogen-regulated genes and estrogen-stimulated
growth of MCF-7 cells (24). Following E2 stimulation and before
microarray hybridization, we assessed the reliability of the system
using quantitative real time PCR (RT-qPCR) to reveal expression
levels of the ER-regulated gene GREB1 [supporting information
(SI) Fig. S1A and ref. 25]. GREB1 expression was reduced in
PLZF-ER cell lines treated without doxytetracycline (Tet) com-
pared to cell lines that do not express the fusion protein (Fig. S1B).
Although following array analysis we did not reveal any miRNAs
with expression changes greater than 2-fold comparing 0 h to 3, 6,
and 12 h (P  0.05) (Table S1), we found that those miRNAs that
increased following E2 in MCF-7 cells decreased in the JP13-Tet-
Off system used as a control (Fig. 1 A and B and Table S1). The
ER-upregulated miRNAs were generated by the processing of 3
paralogous primary miRNAs: pri-mir-17–92, pri-mir-106a-363, and
pri-mir-106b-25 (Fig. 1 A and B, Table S1 and Fig. S2).
To confirm the change of expression detected by the microarray,
we performed RT-qPCR choosing those miRNAs modulated be-
tween 1.2- to 2-fold in cells treated with E2 and those repressed
similarly by PLZF-ER in JP13 cell lines. Firstly, we examined the
expression of the unprocessed pri-mir-17–92 and family members.
Pri-mir-17–92 appeared upregulated within 3 h of E2 treatment
reaching a 4- to 5-fold change in comparison to 0 h (Fig. 1C)
defining it as a new early ER-regulated gene. Levels of expression
were significantly repressed by PLZF-ER (Fig. 1D). Pri-mir-342,
a negative control, showed no changes (Fig. 1 C and D), and we
obtained the same results normalizing the value of expression for
GAPDH, for the snRNAU6 and for the snoRNAU47.We excluded
from this analysis the paralogous pri-mir-106b-25 because the fold
change of the miRNAs encoded by it were considered too low by
our pre-established criteria (Table S1). Furthermore, levels of
expression of the pri-mir-106a-363 inMCF-7 cells appeared too low
to detect (we were not able to amplify it using 7 different sets of
primers from 7 genomic regions). However, it is known that in the
P493–6 B cell line that although there is c-MYC-regulated expres-
sion of typical miRNAs encoded by both pri-mir-17–92 and pri-
mir-106a-363, it is possible to detect the pri-mir-17–92 but not
pri-mir-106a-363, indicating that the latter could either be less
expressed or alternatively processed more rapidly (26). Further-
more, miR-424, miR-450, and miR-542–3p located within 6 kb of
the same genomic region, appeared significantly upregulated by E2
and significantly repressed by PLZF-ER in a perfectly reciprocal
manner (Table S1). We also observed a subset of miRNAs
that were subtly downregulated by the E2-ER complex from 0 to
12 h, and the majority of these belonged to the miR-181 family
(Table S1).
Next, we performed RT-qPCR for miR-18a, miR-19a, miR-19b,
miR-20a,miR-92 (derived frompri-mir-17–92),miR-19b,miR-20b,
miR-92 (from pri-mir-106a-363), miR-424, and miR-181b; the 2
techniques showed an overall correlation (Fig. S3 A–I and Table
S1). Comparing the low levels of expression of the miRNAs to the
higher levels of the pri-miRNAafter stimulation, therewas negative
regulation of miRNA biogenesis, following transcriptional induc-
tion by ER (Fig. 1C and Fig. S3).
C-MYC Directly Regulates the pri-mir-17–92 upon Estrogenic Stimula-
tion. It has already been demonstrated that pri-mir-17–92 is tran-
scriptionally regulated by c-MYC in the P493–6 B cell line during
the G1–S cellular transition phase (26). Since c-MYC mRNA is
upregulated by ER within 1 h of E2 treatment in breast cancer
cells (27), c-MYC could contribute to the increased transcription of
the pri-mir-17–92 upon E2 stimulation. Interestingly, we observed
a half site conserved ERE 70 bp upstream of the c-MYC consensus
site (E-box) of the mir-17–92 promoter (Fig. 2A and Fig. S4). Using
cycloheximide (CHX), we demonstrated that new protein synthesis
Fig. 1. Pri-mir-17–92 is increased by E2 and de-
creased by overexpression of PLZF-ER. (A) MCF-7
cell lines underwent E2 stimulation (10 nM) after
72 h of hormone deprivation. After total RNA ex-
traction and labeling we used a microarray platform
containing probes for 470 human miRNAs. After
hybridization and scanning, raw data were imported
into the Rosetta Resolver system for analysis. A P 
0.01 was used as cut-off for identification of miRNAs
upregulated or downregulated between 0 h versus
6 h. (B) JP13 cells were cultured in the presence or
absence of Tet for 72 h, followed by the addition of
10 nM E2 for 24 h before microarray analysis. Once
again a P 0.01 was used as cut-off for identification
of miRNAs downregulated in JP13  Tet versus
JP13  Tet. (C) MCF-7 cells were maintained in
DMEM (minus phenol red) supplemented with 10%
charcoal-dextran FBS for 3 days and then were either
left untreated or treated with 10 nM E2 for the
indicated time periods. After total RNA extraction,
expression of pri-mir-17–92 and pri-miR-342 was an-
alyzed by RT-qPCR using SYBR green and normalized
toGAPDH. (D) JP13 and MCF-7-TO cells were cultured
in the presence or absence of Tet for 72 h, followed
by the addition of 10 nM E2 for 24 h. Once again,
after total RNA extraction, expression of pri-mir-17–92 and pri-miR-342 were analyzed by RT-qPCR using SYBR green and normalized to GAPDH. The
mean of 3 experiments each performed in triplicate are presented, error bars represent SEM. For RT-qPCR data, the asterisk indicates P  0.05 in
comparison to time 0 h, the double asterisk represents P  0.005 in comparison to time 0 h. P values were obtained using a 2-tailed Student’s t-test.
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is not required exclusively for pri-mir-17–92 expression (Fig. S5)
and because it has been demonstrated that estrogen responsive
genes can contain both ER and c-MYC binding elements located
within close proximity [13–214 bp within the promoter and regu-
lated by both transcription factors in an E2-dependent manner
(28)], we performed chromatin immunoprecipitation (ChIP) assays
for both ER and c-MYC: coprecipitated DNA was analyzed by
amplifying the genomic region containing both consensus sites (Fig.
2A and Fig. S4) by real time PCR (Fig. 2B andC). Although TFF1,
a known estrogen-regulated gene, is confirmed here as regulated by
ER (Fig. 2B), we observed only c-MYC interacting with the
mir-17–92 promoter region analyzed (Fig. 2 B and C). We dem-
onstrated that c-MYC is recruited to the mir-17–92 promoter in
breast cancer cells upon E2 stimulation.
Pri-mir-17–92 Is Negatively Regulated Following DROSHA Cleavage
Prolonging miRNA Maturation over Time. Remarkably, the pri-mir-
17–92 expression is striking compared to the miRNAs that are
produced by its processing (miR-17, miR-18a, miR-19a, miR-19b,
and miR-20a), indicative of modulation of miRNAs biogenesis at
the posttranscriptional level (Figs. 1C, 3A, and Fig. S3). A primary
transcript undergoes a dual processing event, the first in the nucleus
by DROSHA (pre-miRNA production), the second in the cyto-
plasm by DICER. To define the step(s) of miRNA biogenesis in
which regulation occurs, we measured levels of the pri-miR-17–92-
derived pre-miR-18a after E2 treatment. DROSHA pri-mir-17–92
cleavage to pre-miR-18awas not a regulatory or ‘‘rate-limiting’’ step
here because both were induced at similar levels (Fig. 3B). How-
ever, the primers used to amplify the pre-miR-18a also amplify
pri-mir-17–92. Therefore, to establish that we could distinguish
between pri- and pre-miRNA, we stimulated the cell lines with E2
and then separated the small RNA fraction from the large RNA
fraction.We used the largeRNA fraction tomeasure pri-mir-17–92
and the small RNA fraction to measure pre-miR-18a (Fig. S6). As
a further control we measured the pri-mir-17–92 from the small
RNA fraction without obtaining any amplification product. These
data demonstrated that pri-mir-17–92 is induced by the E2–ER
complex, then it is processed by DROSHA releasing the pre-miR-
18a, but the passage between pre-miR-18a and miR-18a is atten-
uated until at least 12 h following initial E2 stimulation. Further-
more, using RT-qPCR, we found that both miR-18a and miR-20a
mature forms increase their levels of expression from 24 to 72 h
after E2 stimulation (Fig. 3 C and D). Analyzing the levels of the
pri-mir-17–92 and the pre-miR-18a from0 to 72 h, we observed that
pri-mir-17–92 is transcriptionally upregulated after 3 h, then DRO-
SHA promptly processes the pri- to the pre-miR-18a, whereas the
formation of themature form from the pre-miR-18a is delayed (Fig.
3E). In addition while the miR-18a levels start to increase at 24 h,
both pri-mir-17–92 and pre-miR-18a levels decline, indicative of the
processing delay we observed (Fig. 3E).
Pri-mir-17–92 Expression Is Correlated with ER Levels in ER-Positive
Primary Breast Cancers. To evaluate ER modulation of the
pri-mir-17–92 at the physiologic level, we examined a corre-
lation between ER mRNA and pri-mir-17–92, and ER
mRNA and pre-miR-18a, in breast cancer tissues by RT-qPCR.
Levels of pri-mir-17–92 were correlated with ER mRNA in
tissues (r2  0.97, P  0.0002, Fig. 4A), further indicating that
ER regulates the expression of this primary miRNA. How-
ever pre-miR-18a was less correlated with ER (r2 0.54, P
0.21, Fig. 4B). Next, we addressed whether pre-miR-18a,
miR-18a, and miR-20a were differentially expressed in pri-
mary breast cancer tissues, comparing the average expression
levels between ER-positive and -negative tumors. Pre-miR-
18a levels were significantly higher in ER-positive tumors
(2.52 0.30) compared with negative tumors (0.90 0.08, P
0.006, Fig. 4C), supporting our data. Moreover, expression
levels of miR-18a showed no significant differences between
the 2 groups of samples (Fig. 4D), indicating that impaired
pre-miR-18a processing to miR-18a occurs in tumors.
MiR-18a, miR-20b, and miR-19b Negatively Modulate the ER Tran-
scriptional Activity After Estrogen Stimulation. Using the available
miRNA target prediction software [TargetScan (29), Pictar
(30), and Pita (31)], we observed whether ER is a potential
target of some or all of these miRNAs. Surprisingly, we found
that miR-18, miR17/20/106, and miR-19 family members were
predicted to target ER. To experimentally validate this
prediction, we chose miR-18a encoded by pri-mir-17–92, miR-
19b encoded by both pri-mir-17–92 and the pri-mir-106a-363,
and miR-20b encoded by the pri-mir-106a-363 (Fig. S2). First,
we addressed whether these miRNAs inf luence ER tran-
scriptional activity. MELN cells (MCF-7 cells, stably trans-
fected with a luciferase reporter gene under the control of an
ERE using the -globin promoter) were transfected with
pre-miR-18a, pre-miR-20b, and pre-miR-negative control
(pre-miR-n.c.). E2-stimulated reporter activity was signifi-
cantly reduced when MELN cells were transfected with pre-
miR-18a and pre-miR-20b, whereas the level of induction was
not affected by pre-miR-n.c. (Fig. 5A). Remarkably, anti-miR-
18a, anti-miR-20b, and anti-miR-19b molecules able to silence
their miRNA function significantly increased reporter activity
(Fig. 5B). The effect of miRNA silencing on luciferase reporter
activity was similar to treatment with anti-miR-17–5p, previ-
ously reported to reduce the transcriptional activity of ER by
downregulating the coactivator AIB1 (21) (Fig. 5B).
Mir-17–5p, miR-106b, and miR-20a are able to negatively reg-
ulate AIB1 protein translation by a direct interaction with the
3-UTR of AIB1 mRNA (21, 22, 32). Because we observed that
miR-17/20/106 and the miR-18 family members potentially target
ER, we evaluated whether the reduction in ER transcriptional
activity induced by miR-20b overexpression was the result of the
contemporary negative regulation of AIB1 and ER and in addi-
tion, whether the reduction in ER transcriptional activity induced
by overexpression of miR-18a was the result of a reduction of ER
protein levels. To address if these miRNAs negatively regulate
either ER and/or AIB1, we overexpressed pre-miR-18a, pre-miR-
19b, pre-miR-20b, and pre-miR-n.c. and measured protein levels.
ER was markedly reduced by the overexpression of all 3 premiRs
analyzed in comparison to either untransfected or pre-miR-n.c.
Fig. 2. c-MYC directly regulates the pri-mir-17–92 upon estrogenic stimula-
tion. (A) Schematic representation of the mir-17–92 cluster genomic region.
Both the c-MYC binding site and a putative ERE half site are indicated. (B)
MCF-7 cells were maintained in estrogen-free medium for 3 days (starvation)
and then either left untreated (vehicle) or treated with 10 nM E2 for 3 h after
which ChIP was performed, followed by real time PCR. The c-MYC interaction
site genomic region is presented. (C) After starvation, MCF-7 cells were treated
with E2 for 12 h before ChIP.
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transfected cells although the reduction with pre-miR-19b was less
pronounced (Fig. 5 C and D). Furthermore, miR-20b downregu-
lated AIB1 because transfection of pre-miR-20b into MCF7 cells
reduced AIB1 protein levels (Fig. 5 C and E). On the other hand,
the transfection of anti-miR-20b increased AIB1 (a dose–response
was also observed here; Fig. 5F). Because a reduction in eitherER
or AIB1 mRNA levels after transfection of precursors was not
observed, it appears likely that this regulation occurs at the protein
translation step (Fig. S7 A and B).
To confirm whether these miRNAs directly target ER, we
inserted into the luciferase reporter vector 4 fragments of the
3-UTR of ER: the full length (FL, containing all of the putative
miRNAs interaction sites), the first half part of the 3-UTR (ERup
for miR-17/20/106 and miR-18), a fragment containing just the
putative miR-18 family interaction sites (ER1), and finally a frag-
ment corresponding to the second half section, containing the
miR-19 family interaction sites (ER2) (Fig. 6A). Transfection of
miR-18a, miR-19b, and miR-20b, derived from pri-mir-17–92 and
pri-mir-106a-363, were used to investigate direct interactions with
the 3-UTR of ER constructs and we demonstrated that these
miRNAs profoundly downregulate luciferase activity for the con-
structs containing miRNA interaction sites, but not for the ones in
which these sites are absent (Fig. 6B). This indicates direct targeting
of ER by a number of miRNAs derived from these paralogous
primary miRNAs. We did not observe any downregulation of
luciferase reporter activity upon miR-17–5p overexpression, ac-
cording to a recent report (33).
Discussion
In this study we were able to classify miRNAs upregulated by
estrogen as the members encoded by the paralogous tran-
scripts pri-mir-17–92 and pri-mir-106a-363. For individual
miRNAs small changes were observed, but as multiple mature
molecules derived from these primary transcripts target ER
and/or AIB1 this increases both the overall level of the
miRNAs regulating these 2 proteins after E2 induction and the
effects of silencing; it is known that multiple molecules affect-
ing a single target increase their inhibitory effect (34).
Changes in pri-mir-17–92 were significantly greater than the
miRNAs derived from it, implicating inhibition during miRNA
biogenesis: DROSHA cleavage of pri- to pre-miRNAs occurred
rapidly, indicating that this step is not rate limiting (Fig. S8). Such
regulation however has been described regarding let-7 family
members during stem cell differentiation: LIN-28 is able to interact
with pri-let-7 and/or pre-let-7 impairing its processing (12, 15). It
has also been reported that c-MYC downregulates let-7 maturation
increasing the transcription of LIN-28b in P493–6 B cell lines (35).
Furthermore, it has been shown that the RNA binding protein
KSRP, interacting with DICER, promotes the biogenesis of a
subset of miRNAs comprising miR-20a and miR-106a in both
HeLa and NIH 3T3 cells (36). Because we did not observe any
estrogen-mediated upregulation of LIN-28 and/or any expression of
LIN-28b, or any estrogen-mediated downregulation of DICER
and/or KSRP in our models, this indicates that these factors are not
responsible. Our data indicate that pri-mir-17–92 (not only let-7), is
regulated after induction. Additionally, many expression studies
note discordance in the levels of mature miRNAs derived from
polycistronic precursors. Although regulation of pri-mir-17–92-
derivedmicroRNAs could not be explained by the candidate factors
we tested, the apparent prevalence of regulatedmiRNAmaturation
strongly suggests involvement of additional RNA binding proteins
in this process.
The importance of miRNA activity in breast cancer biology is
also highlighted by the finding that a number of miRNAs show a
differential expression between ER positive and ER negative
breast cancers (37, 38). We demonstrated that pri-mir-17–92 ex-
pression is highly correlated with the level of ER in breast cancers,
and that pre-miR-18a derived fromDROSHA-pri-mir-17–92 cleav-
age is also significantly more expressed in ER-positive compared
to ER-negative tumors. This indicates that a specific increase of
this pri-miRNA also occurs in physiologic conditions. It is inter-
esting that miR-18a produced by pri-mir-17–92 is not expressed
Fig. 3. Pri-mir-17–92 is negatively regulated follow-
ing DROSHA cleavage prolonging miRNA matura-
tion over time. (A) Comparison of the levels of ex-
pression between pri-mir-17–92 (normalized to
GAPDH) and miRNAs encoded from this cluster (nor-
malized to U47). The mean of 3 experiments each
performed in triplicate are presented, error bars
represent SEM. (B) After starvation expression levels
of both pri-mir-17–92 and pre-miR-18a has been
analyzed by RT-qPCR using SYBR green and normal-
ized to U6 snRNA followed E2 treatment as indi-
cated. The mean of 3 experiments each performed in
triplicate are presented, error bars represent SEM.
The asterisk indicates P 0.05 in comparison to time
0 h, the double asterisk represents P  0.005 in
comparison to time 0 h. P values were obtained using
a 2-tailed Student’s t-test. (C) After starvation ex-
pression levels of miR-18a, miR-20a, and miR-342
were analyzed by RT-qPCR and normalized to U47
snRNA. The mean of 3 experiments each performed
in triplicate are presented, error bars represent SEM.
The asterisk indicates P  0.05 in comparison to
vehicle treatment, the double asterisk represents P
0.005 in comparison to vehicle treatment. P values
were obtained using a 2-tailed Student’s t-test. (D)
Representation of miR-18a, miR-20a, and miR-342
levels (normalization to U47 snoRNA) from 0 to 72 h of E2 treatment by RT-qPCR. The mean of 3 experiments each performed in triplicate are presented,
error bars represent SEM. (E) Representation of the miR-18a (normalization to U47), pre-miR-18a and pri-mir-17–92 levels (normalization to U6) from
0 to 72 h of E2 treatment. The mean of 3 experiments each performed in triplicate are presented, error bars represent SEM.
Castellano et al. PNAS  September 15, 2009  vol. 106  no. 37  15735
CE
LL
BI
O
LO
G
Y
preferentially in ER-positive tumors. This further suggests that
ER-positive tumors escape the inhibitory targeting of ER caused
by miRNAs by in turn downregulating DICER processing of those
miRNAs during tumor progression. Here we demonstrate that the
factors implicated in attenuation of miRNA processing are also
active in cancer tissues themselves.
The modulation of the pri-mir-17–92 by ER appears mediated
by the c-MYC oncogene by its direct interaction with themir-17–92
promoter. It has been reported that c-MYC directly downregulates
the expression of a set of miRNAs in B cells (39). Because we have
not observed any reduction of those after estrogenic stimulation, we
conclude that the upregulation of pri-mir-17–92 through ER-c-
MYC is specific to breast cells.
By forming a complex with several coactivators or corepres-
sors, ER transcriptionally modulates several genes implicated
in cell proliferation and apoptosis such as BCL2, c-MYC, and
cyclin D1. AIB1, SRC1, and TIF2 belong to the same family
of coactivators that interact and collaborate with ER in the
transcriptional regulation of target genes (40). MiR-17–5p and
miR-20a encoded by pri-mir-17–92, and the homologue miR-
106b, downregulate the translation of AIB1 (21, 22, 32).
Because following E2-mediated upregulation: (i) miR-18a,
miR-19b, and miR-20b downregulate ER and (ii) miR-20a,
miR-17–5p, miR-106a, and miR-20b downregulate AIB1, we
conclude that both primary transcripts are implicated in the
regulation of ER transcriptional activity upon estrogenic
stimulation. Several studies have indicated that after estro-
genic induction, both ER and AIB1 are rapidly downregu-
lated. This attenuation occurs at transcriptional, posttranscrip-
tional, and posttranslational levels (5–8). We propose here the
translational regulation by miRNAs as a further step of ER
transcriptional activity attenuation after estradiol-mediated
ER activation. Interestingly, this regulation occurs especially
at a later time and in a negative feedback loop because DICER
pri-mir-17–92 processing appeared inhibited after early ER
upregulation (Fig. S8).
Methods
MiRNA Microarray. Isolated RNA was labeled using the Agilent labeling kit
following the manufacturer’s instruction (Agilent Technologies). The Agilent
human (V1) miRNA microarray platform, containing probes for 470 human (and
64 viral miRNAs from the Sanger database v9.1), was used to perform miRNA
expression profiling.
RT-qPCR Assay. For RT-qPCR assays, cDNA was synthesized from 1 g of
purified Dnase-treated RNA by the SuperScript III First-Strand cDNA syn-
thesis system (Invitrogen); RT-qPCR was performed on a 7900HT Thermo-
cycler using the Power SYBR green PCR master mix (both from Applied
Biosystems). For detection of mature miRNAs, the TaqMan MicroRNA assay
kit (Applied Biosystems) was used. Sequences of primers used are provided
in Table S2.
ChIP. Cross-linked chromatin was prepared from MCF-7 cells as described
previously with minor modifications (43). Aliquots of 20 g were incubated
Fig. 4. ER modulates pri-mir-17–92 in breast cancer tissues. (A) Expression
levels of ER and pri-mir-17–92 (Pearson correlation 0.97) or (B) pre-miR-18a
(Pearson correlation 0.54) was measured by RT-qPCR in ER-positive breast
cancers. (C) RT-qPCR showed that expression levels of pre-miR-18a are signif-
icantly higher in ER-positive than in ER-negative tumors (unpaired, 2-tailed
Student’s t-test P 0.006). Error bars represent SEM. (D) RT-qPCR showed that
expression levels of miR-18a are not different between ER-positive and
ER-negative tumors (unpaired, 2-tailed Student’s t-test P  0.18). Error bars
represent SEM.
Fig. 5. MiR-18a, miR-19b, and miR-20b suppress ER-
mediated signaling. (A) Luciferase activity in MELN
cells untransfected or transiently transfected for 48 h
with pre-miR-18a, pre-miR-20b, and pre-miR-n.c. in the
absence or presence of 10 nM of E2 for 24 h. (B)
Luciferase activity in MELN cells transiently transfected
for 48 h with anti-miR-17–5p, anti-miR-18a, anti-miR-
19b, anti-miR-20b, anti-miR-n.c. or untransfected in
the absence or presence of 10 nM of E2 for 24 h. (C)
Western blot showing ER, AIB1, and -actin in MCF-7
cells untransfected or transiently transfected with pre-
miR-18a, pre-miR-19b, pre-miR-20b, and pre-miR-n.c.
(D) Densitometric analysis of ER Western blot shown
inCnormalized to-actin. (E) Densitometric analysis of
AIB1 Western blot (shown in C normalized to -actin.
The mean of 3 independent experiments are pre-
sented, error bars represent SEM. (F) Western blots
showing AIB1 and -actin in MCF-7 cells transfected
with anti-miR-n.c. and anti-miR-20b at 10, 30, and 100
nM concentrations. One representative experiment
from 3 independent experiments is shown.
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overnight with 2 g of c-Myc (sc-764) and ER (sc-543) antibodies (Santa
Cruz Biotechnology) or without (mock controls) in a total volume of 1 mL
and immunoprecipitated. Triplicate samples of 5 L of immunoprecipi-
tated genomic DNA were amplify by real time PCR. Values are expressed as
fold of enrichment with respect to input DNA. Primer sequences used in this
assay are listed in Table S2.
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